MALCOV Sequencing_BurkinaFaso

*This is the BioProject for the sequencing data collected from Burkina Faso as part of the MALCOV project*The molecular epidemiology of SARS-CoV-2 in some LMICs is limited, and there is a need for more cost-accessible technologies to help close data gaps for surveillance of SARS-CoV-2 variants. To address this, we have developed two high-resolution melt curve (HRM) assays that target key variant-defining mutations in the SARS-CoV-2 genome, which give unique signature profiles that define different SARS-CoV-2 variants of concern (VOCs). Extracted RNA from SARS-CoV-2 positive samples collected from 205 participants (112 in Burkina Faso, 93 in Kenya) on the day of enrolment in the MALCOV study (Malaria as a Risk Factor for COVID-19) between February 2021 and February 2022 were analysed using our optimised HRM assays and compared to Next Generation Sequencing (NGS) on Oxford Nanopore MinION

本条目为MALCOV项目中采集自布基纳法索的测序数据对应的生物项目数据库（BioProject）。当前部分低收入和中等收入国家（Low- and Middle-Income Countries, LMICs）的SARS-CoV-2分子流行病学研究存在明显局限，亟需具备成本可及性的技术手段以填补新冠病毒变异株监测领域的数据空白。为此，本研究开发了两种高分辨率熔解曲线（high-resolution melt curve, HRM）检测方法，靶向SARS-CoV-2基因组中关键的变异株特征突变，可生成用于区分不同新冠病毒关切变异株（variants of concern, VOCs）的独特特征图谱。本研究对2021年2月至2022年2月期间参与MALCOV研究（疟疾作为COVID-19的危险因素）的205名受试者的新冠病毒阳性样本（其中布基纳法索112份、肯尼亚93份）在入组当日提取的RNA，采用优化后的HRM检测方法开展分析，并与基于牛津纳米孔MinION平台的下一代测序（Next Generation Sequencing, NGS）结果进行比对。